文献速递甲状腺疾病

妊娠与分化型甲状腺癌进展:一项倾向性评分匹配的回顾性队列研究

Pregnancy and Progression of Differentiated Thyroid Cancer: A Propensity Score-Matched Retrospective Cohort Study.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

该回顾性队列研究纳入2012年1月至2022年12月在北京大学第三医院就诊的311例20至45岁女性,经倾向性评分匹配后比较妊娠组(n=48)与非妊娠组(n=154)的分化型甲状腺癌进展。中位观察2.5年,两组在无进展生存、无肿瘤增大生存及无淋巴结转移生存上均无显著差异。作者认为妊娠似乎与手术治疗前分化型甲状腺癌进展无关,需进一步前瞻性队列研究。

要点

  • 倾向性评分匹配后妊娠组48例与非妊娠组154例基线可比。
  • 平均观察2.5年,两组无进展生存期风险比HR=0.96(95%CI 0.56-1.65,P=0.895)。
  • 无肿瘤增大生存HR=0.99(95%CI 0.56-1.76,P=0.969),无淋巴结转移生存HR=0.67(95%CI 0.21-2.13,P=0.498)。

核心结论

  • 妊娠似乎与手术治疗前分化型甲状腺癌的无进展生存无关。
  • 作者指出需进一步前瞻性队列研究将该发现转化至临床实践。

研究设计与样本

  • 回顾性队列研究,于2012年1月至2022年12月在北京大学第三医院开展。
  • 纳入311例20至45岁符合条件的女性。
  • 采用倾向性评分匹配按基线年龄、肿瘤大小、肿瘤类型及桥本甲状腺炎状态匹配妊娠组(n=48)与非妊娠组(n=154)。
  • 采用按匹配对分层的Cox比例风险模型估计妊娠与分化型甲状腺癌进展的关联。

主要发现

  • 匹配后妊娠组与非妊娠组基线可比(标准化差异<10%且P>.05)。
  • 平均观察2.5年,妊娠组与匹配非妊娠组的分化型甲状腺癌无进展生存无差异(HR=0.96;95%CI 0.56至1.65;P=.895)。
  • 妊娠组与匹配非妊娠组的无肿瘤增大生存无差异(HR=0.99;95%CI 0.56至1.76;P=.969)。
  • 妊娠组与匹配非妊娠组的无淋巴结转移生存无差异(HR=0.67;95%CI 0.21至2.13;P=.498)。
  • 术后病理特征在妊娠组与非妊娠组间无显著差异(P>.05)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文结论指出需进一步前瞻性队列研究将该发现转化至临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT AND OBJECTIVE: Differentiated thyroid cancer (DTC) is very common in women of reproductive age. However, it remains unclear whether pregnancy is associated with DTC progression before surgical treatment. METHODS: This retrospective cohort study, conducted at the Peking University Third Hospital in Beijing, China between January 2012 and December 2022, included 311 eligible women aged 20 to 45 years. To control for potential confounders, we first used propensity score matching (PSM) to match the pregnant group (n = 48) with the nonpregnant group (n = 154) on age, tumor size, tumor type, and Hashimoto's thyroiditis status at baseline, and then used Cox proportional risk models stratified by the matched pairs to estimate the association of pregnancy with DTC progression. RESULTS: After PSM, the pregnant and nonpregnant groups were well comparable at baseline (standardized difference < 10% and P > .05). Over an average observation period of 2.5 years, we observed no difference between the pregnant group and the matched nonpregnant group in DTC progression-free survival (hazard ratio [HR] = 0.96; 95% CI, 0.56 to 1.65; P = .895), tumor enlargement-free survival (HR = 0.99; 95% CI, 0.56 to 1.76; P = .969) or lymph node metastasis-free survival (LNM) (HR = 0.67; 95% CI, 0.21 to 2.13; P = .498). The postoperative pathological characteristics also showed no significant difference between the pregnant and nonpregnant groups (P > .05). CONCLUSION: Pregnancy seemed to be irrelevant to DTC progression-free survival before surgical treatment. Further prospective cohort studies are needed to translate this finding into clinical practice.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Xiao WC, Li X, Shan R, et al. Pregnancy and Progression of Differentiated Thyroid Cancer: A Propensity Score-Matched Retrospective Cohort Study. J Clin Endocrinol Metab. 2024. PMID: 37738427. doi:10.1210/clinem/dgad557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。